Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
FDA has approved a supplemental new drug application for Stendra (avanafil) taken early as ~15 minutes before sexual activity.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Findings seen in economically disadvantaged men with newly diagnosed prostate cancer.
Risk is greater in patients managed with watchful waiting than in those who undergo radical treatment.
Only 10% of men aged 45-69 years who progress from no or mild to moderate or severe lower urinary tract symptoms are treated, study finds.
In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.
Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.